GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Total Inventories

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Total Inventories : $40.9 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Total Inventories?

Xeris Biopharma Holdings's total inventories for the quarter that ended in Mar. 2024 was $40.9 Mil. Xeris Biopharma Holdings's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $39.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Xeris Biopharma Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.42.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Xeris Biopharma Holdings's Days Inventory for the three months ended in Mar. 2024 was 609.12.

Inventory Turnover measures how fast the company turns over its inventory within a year. Xeris Biopharma Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.15.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Xeris Biopharma Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.98.


Xeris Biopharma Holdings Total Inventories Historical Data

The historical data trend for Xeris Biopharma Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Total Inventories Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial 2.18 8.35 18.12 24.74 38.84

Xeris Biopharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.04 36.54 38.14 38.84 40.88

Xeris Biopharma Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Xeris Biopharma Holdings  (NAS:XERS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Xeris Biopharma Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(87.352+0.75 * 37.414+0.5 * 40.878-345.794
-0-0)/148.224
=-1.42

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Xeris Biopharma Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=39.858/5.971*365 / 4
=609.12

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Xeris Biopharma Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=5.971 / 39.858
=0.15

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xeris Biopharma Holdings's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=39.858 / 40.638
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Xeris Biopharma Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Executives
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015